Cellworks Unveils a Breakthrough in Predicting Chemo-Immunotherapy Benefit for Patients with Metastatic NSCLC

(CLWK) BARCELONA--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Best-in-Class PTRS, today announced results from the landmark myCare-040 clinical study, which demonstrates the predictive capability of the Cellworks Platform in guiding chemotherapy treatment decisions for patients with metastatic non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs). The findings advance a personalized approach to NSCLC treatment selection that m